Due to the COVID-19 pandemic, these meetings are being replaced with a webinar in Autumn 2020.
Sign up for more information when it becomes available.
A focus on RAAS inhibition and hyperkalaemia management
What are they about?
We have been listening to your feedback that you would like more case-based and practical learning. We are delighted to be able offer these new webinars, led by experts in the field, that will discuss the practical approach to the management of hyperkalaemia in patients with cardiorenal disease.
This will include the approach to broad-spectrum presentations, from those with potentially life-threatening hyperkalaemia through to the impact of high potassium on the use of prognostically important renin-angiotensin-aldosterone system (RAAS) inhibitors. Using case examples, they will discuss and guide on how to optimally manage such patients and avoid pitfalls that might have adverse consequences to patients. Wherever possible, local pathways will be used and multidisciplinary discussion encouraged.
At the end of each webinar, delegates will have learned/contributed to multidisciplinary discussion around the following topics:
Sign up for more information
Who can attend?
These webinars can only be attended by healthcare professionals. They are aimed at anyone treating the cardiorenal patient particularly those working in heart failure, cardiology, nephrology, care of the elderly, general medicine, general practitioners, clinical pharmacists and allied disciplines.
We thank Vifor Pharma UK for their award of an unrestricted educational grant to support this webinar.